CELEX: 62012TA0493
Language: en
Date: 2014-09-24 00:00:00
Title: Case T-493/12: Judgment of the General Court of 24 September 2014  — Sanofi v OHIM — GP Pharm (GEPRAL) (Community trade mark — Opposition proceedings — International registration designating the European Community — Word mark GEPRAL — Earlier international word mark DELPRAL — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009)

3.11.2014   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 388/12
            
         Judgment of the General Court of 24 September 2014 — Sanofi v OHIM — GP Pharm (GEPRAL)
   (Case T-493/12) (1)
   
   ((Community trade mark - Opposition proceedings - International registration designating the European Community - Word mark GEPRAL - Earlier international word mark DELPRAL - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009))
   2014/C 388/14
   Language of the case: English
   
      Parties
   
   
      Applicant: Sanofi SA (Paris, France) (represented by: C. Hertz-Eichenrode, lawyer)
   
      Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: P. Geroulakos, acting as Agent)
   
      Other party to the proceedings before the Board of Appeal of OHIM: GP Pharm SA (Sant Quinti de Mediona, Spain)
   
      Re:
   
   Action brought against the decision of the Second Board of Appeal of OHIM of 5 September 2012 (Case R 201/2012-2), concerning opposition proceedings between Sanofi SA and GP Pharm SA.
   
      Operative part of the judgment
   
   The Court:
   
               1.
            
            
               Annuls the Decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM) of 5 September 2012 (Case R 201/2012-2), concerning opposition proceedings between Sanofi SA and GP Pharm SA;
            
         
               2.
            
            
               Orders OHIM to pay the costs.
            
         
      (1)  OJ C 26, 26.1.2013.